Background: Dermatophytosis is a worldwide health-related problem, affecting 20-25% population globally. Once it was very easy to treat with either topical or systemic antifungal agents but now become a challenge for dermatologists because of increasing resistance against conventional antifungals fluconazole, itraconazole, and terbinafine with standard dosages and duration for the last few years in Bangladesh. Search for an effective new oral antifungal agent now become essential. Aim of the Study: To evaluate the efficacy and safety of the new antifungal agent voriconazole in the treatment of refractory and recurrent cases of dermatophytosis. Methods: The study was conducted in the outdoor patient department of Jahurul Islam Medical College Hospital, a rural-based tertiary care teaching hospital on 100 patients with extensive, recurrent, treatment failure cases of dermatophytosis. The clinical diagnosis was confirmed by KOH microscopic examination. Patients were given oral voriconazole at a dose of 200mg twice daily one hour after food for 4 weeks. The patients were followed up at week 2 to assess clinical response and any adverse effects from the prescribed drug. The final efficacy assessment was made at the end of week 4 with the combined evaluation of mycological results and the sum of clinical scores according to a 4-point physician assessment scale of 0-3 (0-absent, 1- mild, 2-moderate, 3- severe). Results: A total of 100 patients completed the clinical trial. Among them 52% were male and 48% were female. The 15-25 year’s age group was 34% and the 26-35 year’s age group was 24%. Majority of patients 56% had a duration between 6 months to <1 year. Of all patients, 100% had tinea corporis and tinea cruris was present in 85%. Involvement with outdoor work was present in 60% of cases. A Complete cure was seen in 82%, mycological cure was seen in 12%, and failure to treatment was seen in 6% cases. Adverse effects were seen in 40% of patients with visual disturbances in 27%, followed by headache and skin rash in 5% and 3% respectively Conclusion: Based on the result, it can be concluded that voriconazole is a highly effective and safe oral antifungal agent that can be used in the treatment of recurrent therapy-resistant cases of dermatophytosis.